Our commitment to safety communication

Verified safety updates from ongoing ocrelizumab clinical trials and post-marketing experience

As of October 2021, more than 225,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 450,000 patient years1

>7,000 patients in clinical trials and open-label extension

>220,000 patients with post-marketing experience

 

Our commitment to safety communication

Verified safety updates from ongoing ocrelizumab clinical trials and post-marketing experience

As of October 2021, more than 225,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 450,000 patient years1

>7,000 patients in clinical trials and open-label extension

>220,000 patients with post-marketing experience

 

References

1. Roche data on file: 31 October 2021, post-marketing experience; 30 November 2020, clinical trials data cut-off